Docetaxel and Epirubicin in Advanced Gastric Cancer
Recruitment status was Recruiting
- Study rationale:There is no standard regimen for the advanced and/or metastatic gastric cancer patients who relapsed after adjuvant chemotherapy or failed to first systemic chemotherapy.
- Primary Objectives:To evaluate overall response rate according to the RECIST criteria and To investigate time to response
- Design:single-center, Open label, Phase II study. docetaxel 75mg/m2 administered on day 1 as intravenously combined with intravenous Epirubicin 60mg/m2 given day 2 every 3 weeks.
- Primary endpoints:
1)Efficacy:overall response rate according to the RECIST criteria, time to response, duration of response, and time to treatment failure. 2)Safety-Adverse events and laboratory tests, graded according to the NCI CTCAE (version 3.0).
|Study Design:||Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||A Phase II Study of Docetaxel and Epirubicin Combination in Patients With Advanced Gastric Cancer.|
|Contact: Jae Yong Chofirstname.lastname@example.org|
|Korea, Republic of|
|Yongdong Severance Hospital||Recruiting|
|Seoul, Korea, Republic of|
|Principal Investigator:||Jae Yong Cho||Yonsei University|